Capricor Therapeutics Inc (NASDAQ:CAPR) Receives Average Rating of "Buy" from Brokerages

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) have earned a consensus rating of "Buy" from the six research firms that are currently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $34.50.

Several equities analysts recently weighed in on the company. Piper Sandler initiated coverage on Capricor Therapeutics in a research report on Monday, October 21st. They set an "overweight" rating and a $35.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, January 2nd. Finally, Cantor Fitzgerald increased their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday, November 14th.

Capricor Therapeutics Stock Performance

Shares of Capricor Therapeutics stock traded up $0.40 on Friday, hitting $15.95. 1,955,667 shares of the company's stock were exchanged, compared to its average volume of 663,709. Capricor Therapeutics has a 1 year low of $3.52 and a 1 year high of $23.40. The company has a 50-day simple moving average of $14.17 and a 200-day simple moving average of $13.09. The stock has a market capitalization of $725.25 million, a PE ratio of -15.05 and a beta of 4.08.

Institutional Trading of Capricor Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CAPR. Summit Investment Advisors Inc. grew its holdings in Capricor Therapeutics by 54.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock valued at $53,000 after buying an additional 1,345 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Capricor Therapeutics by 22.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company's stock worth $178,000 after acquiring an additional 2,361 shares during the last quarter. Invesco Ltd. boosted its position in shares of Capricor Therapeutics by 20.5% during the fourth quarter. Invesco Ltd. now owns 14,678 shares of the biotechnology company's stock worth $203,000 after acquiring an additional 2,500 shares during the last quarter. Russell Investments Group Ltd. grew its stake in Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock valued at $64,000 after acquiring an additional 2,947 shares in the last quarter. Finally, Corebridge Financial Inc. increased its holdings in Capricor Therapeutics by 32.2% in the 4th quarter. Corebridge Financial Inc. now owns 18,212 shares of the biotechnology company's stock valued at $251,000 after acquiring an additional 4,434 shares during the last quarter. Institutional investors own 21.68% of the company's stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.